Drug Trial Radar · NCT06592664
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2030
Primary completion
Jan 2035
Study completion Jan 2040
Sponsor
- Lead sponsor
- Lisata Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment Participants will: * Visit the clinic three times every 28 days for treatment and tests * Have CT or MRI scans every 8 weeks while on treatment
Conditions
- Pancreas Cancer
- Pancreatic Carcinoma
- Pancreas Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Unresectable Pancreatic Cancer
- Metastatic Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
certepetideDrug
certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
nab-paclitaxelDrug
nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
gemcitabineDrug
gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
placebo matching certepetideDrug
placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
certepetideDrug
certepetide given as two IV pushes over 1 minute when standard treatment(s) are given
placebo matching certepetideDrug
placebo given as an IV infusion over 4 hours when standard treatment(s) are given
placebo matching certepetideDrug
certepetide given as a slow IV push over 1 minute when standard treatment(s) are given
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: 30 days after treatment discontinuation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.